Alimentary Pharmacology & Therapeutics
Fecha de publicación: 27 May 2019
DOI: https://doi.org/10.1111/apt.15281
Autores: Anna M. Buchner, Gary R. Lichtenstein
Background: Patients with IBD have an altered gut microbiome; these alterations are defined as dysbiosis. Reduced diversity, abundance of pro‐inflammatory bacteria such as Enterobacteriaceae, reduction in phyla with anti‐inflammatory properties such as Firmicutes have been reported. Mechanisms of efficacy of pharmacotherapy or markers of response and relationships to dysbiosis have been of special interest.
Leer más
Comentarios
Para dejar un comentario antes debes iniciar sesión:
¿No tienes una cuenta?
Regístrate a través de éste enlace.